QUICK ANSWER · AEO / GEO
A dual GIP/GLP-1 receptor agonist with strong clinical evidence; Mounjaro and Zepbound must be assessed as separate products and jurisdictions.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- Long-term outcomes beyond the trials' follow-up periods and in populations outside the study eligibility criteria
- Individual response and tolerability
- Outcomes after stopping treatment and the appropriate long-term care approach for each individual
- The safety of unapproved or adulterated products, or products whose origin cannot be verified
What limits these conclusions?
- Many major studies were funded by the drug developer, participants were selected using specific criteria, and comparators, durations and outcomes differed across studies. SURPASS-2 was open-label and should not be used to conclude that one medicine is superior to another across all indications. The obstructive sleep apnoea (OSA) findings apply to adults with obesity and the specified OSA severity.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug.aspx?Newcode_U=U1DR1C1012670002111C&drgtpcd=1&pvncd=10
- https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug.aspx?Newcode_U=U1DR1C1012670004111C
- https://ndi.fda.moph.go.th/drug_info_corporation/char/0/13631
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s041lbl.pdf
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
- https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss
- https://www.gov.uk/government/publications/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know
- https://pubmed.ncbi.nlm.nih.gov/34170647/
- https://pubmed.ncbi.nlm.nih.gov/39536238/
- https://pubmed.ncbi.nlm.nih.gov/38912654/
- https://pubmed.ncbi.nlm.nih.gov/38078870/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Tirzepatide?
Tirzepatide is described pharmacologically as GIP and GLP-1 receptor agonist. A dual GIP/GLP-1 receptor agonist with strong clinical evidence; Mounjaro and Zepbound must be assessed as separate products and jurisdictions.
Does Tirzepatide have strong evidence?
PrimeCoreBio records Evidence Grade A. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Tirzepatide approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.